Openbookopenbook
Equity
Grifols SA ADR(GRFS)
USD --+0.00%
Reward67High
Risk49Moderate
75%Data
3.5% dividend yield
GRFS
+0.0 · +0.00%
USD · NASDAQ
Grifols SA ADR | Healthcare
Deep Value
Market Cap:5.29Bn
ⓘ
Reward Rating
67
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
49
Moderate
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GRFS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for GRFS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $10.87.

What is Grifols SA ADR?

, together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.

GRFS · Verdict

Solid reward · moderate risk

GRFS stands out on valuation and growth, but watch the balance sheet signal.

Based on 88% data coverage

GRFS · Verdict

What’s working & what to watch

Strengths 3

  • Valuation95/100

    P/E 8.8× · PEG 0.23

  • Growth79/100

    Rev +6.0% CAGR · earnings +27.8%

  • Cash flow74/100

    10% free-cash-flow margin

Watchouts 2

  • Balance sheet36/100

    Interest covered 2.0×

  • Profitability45/100

    5% net margin · 7% ROE

Model-based scoring. For information only — not financial advice.

What is Grifols SA ADR?

, together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 5.29B, and a P/E ratio of 10.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (67)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap5.29B
P/E Ratio10.3733
Dividend Yield3.55%
Beta1.192
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.